The effect isn't instant, and it's not a substitute for adequate protein or sunscreen, but it can be a useful layer of support
Mounjaro (tirzepatide) the first dual GLP-1/GIP agonist to reach the market is only approved for treating type 2 diabetes at the moment, but is growing strongly in that indication and is heading for a potential approval in obesity before the end of the year
[1] [2] It does not hold a marketing authorisation from the MHRA or EMA, and is therefore only available through approved clinical trials or, in exceptional circumstances, via a regulated NHS specials supply route
Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy
Practical Laboratory Considerations Shifting between these peptides requires careful planning, particularly during dose escalation when gastrointestinal side effects are most pronounced
Semaglutide dosing protocol Semaglutide for weight management (marketed as Wegovy) uses a 16-week titration